IL23A and enthesitis: Guselkumab, a monoclonal antibody targeting the IL-23 subunit alpha (p19 subunit) currently approved for the use in plaque PsO, is under evaluation for the use also in PsA with significant improvement in particular for manifestations such as enthesitis and dactylitis (33).